Format

Send to

Choose Destination
Int Psychogeriatr. 2012 Aug;24 Suppl 1:S35-40. doi: 10.1017/S1041610212000543.

Gingko biloba extract EGb 761®: clinical data in dementia.

Author information

1
Clinic of Geriatric Psychiatry and Psychotherapy, Alexian Hospital, Krefeld, Germany. ralf.ihl@t-online.de

Abstract

Research into Gingko biloba extract EGb 761® has been ongoing for many years. Early studies showed that the extract was superior to placebo in improving symptoms of dementia, and this has been confirmed by more recent research. The GINDEM-NP, GOTADAY and GOT-IT! studies showed that 240 mg/day EGb 761® improved cognitive function, neuropsychiatric symptoms, activities of daily living, and quality of life in patients with mild to moderate dementia compared with placebo, with results reproducible in independent trials. The strength of the effect in terms of improvements in neurosensory symptoms associated with old age and dementia was strong enough to be detected by caregivers and independent clinicians. A combination of 240 mg/day EGb 761® and 10 mg/day (initially 5 mg/day) donepezil was also more effective than either drug alone. Regarding the improvement of neuropsychiatric symptoms, a cross-comparison of studies with different antidementia agents suggests that EGb 761® is at least as effective as memantine, galantamine, and donepezil. Safety data revealed no important safety concerns with EGb 761®.

PMID:
22784427
DOI:
10.1017/S1041610212000543
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Cambridge University Press
Loading ...
Support Center